<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564197</url>
  </required_header>
  <id_info>
    <org_study_id>M17FNN</org_study_id>
    <secondary_id>CA209-9XC</secondary_id>
    <nct_id>NCT03564197</nct_id>
  </id_info>
  <brief_title>18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC</brief_title>
  <official_title>18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter single arm biomarker exploration and validation study. Eighty patients with&#xD;
      NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab&#xD;
      or 2nd line and beyond PD-(L)1 immunotherapy monotherapy according to EMA label and national&#xD;
      guidelines will be enrolled in this trial. All subjects will undergo a whole body 18F-PD-L1&#xD;
      PET/CT scan before start of nivolumab containing treatment. Patients will continue treatment&#xD;
      until disease progression, withdrawal of patient consent or unacceptable toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18F-PD-L1 PET/CT scan to predict durable reponse to nivolumab containing treatment in&#xD;
      patients with NSCLC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival of &gt;= 9 months</measure>
    <time_frame>From date of registration until the date of progression-free survival &gt;= 9 months (according to RECIST1.1)</time_frame>
    <description>The outcome measures of 18F-PD-L1 PET/CT related to the progression-free survival at 9 months according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of registration until the date of first documented progression assessed up to 5 months</time_frame>
    <description>The outcome measures of 18F-PD-L1 PET/CT related to the date of the first documented tumor progression as determined by modified RECIST, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of registration until the date of death assessed up to 12 months</time_frame>
    <description>The outcome measures of 18F-PD-L1 PET/CT related to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor and stromal PD-L1 IHC.</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Correlation between PD-L1 expression measured by 18F-PD-L1 PET/CT and PD-L1 expression measured by IHC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>NSCLC Stage IV</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>nivolumab containing treatment according to label</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-PD-L1</intervention_name>
    <description>18F-PD-L1 PET/CT scan</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <other_name>tracer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a histologically or cytologically confirmed diagnosis of stage IV, EGFR WT and&#xD;
             EML4-ALK fusion negative NSCLC. Mutational testing is not necessary in patients with&#xD;
             squamous NSCLC.&#xD;
&#xD;
          2. Eligible for first line chemo-immunotherapy, first line nivolumab + ipilimumab or 2nd&#xD;
             line and beyond PD-(L)1 immunotherapy monotherapy.&#xD;
&#xD;
          3. Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          4. Be &gt;= 18 years of age on day of signing informed consent.&#xD;
&#xD;
          5. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
          6. Must provide tissue from a histological biopsy of a tumor lesion that is not radiated&#xD;
             prior to biopsy and obtained after the last line of systemic therapy, to determine the&#xD;
             actual PD-L1 status.&#xD;
&#xD;
          7. Have a performance status of 0-1 on the ECOG Performance Scale.&#xD;
&#xD;
          8. Demonstrate adequate hematologic and organ function, defined by the following&#xD;
             laboratory results. All screening laboratory tests should be performed within 30 days&#xD;
             prior to day 1 (PET imaging):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500 cells/µL&#xD;
&#xD;
               -  WBC count ≥ 2000 cells/µL&#xD;
&#xD;
               -  Platelet count ≥ 100.000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 5.6 mmol/L&#xD;
&#xD;
               -  AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases are present)&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN (except subjects with known Gilbert disease, who can&#xD;
                  have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
               -  Serum Creatinine ≤ 1.5 x ULN OR measured of calculated creatinine clearance (GFR&#xD;
                  can also be used in place of creatinine or CrCl) ≥ 40 mL/min for subject with&#xD;
                  creatinine levels &gt; 1.5 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days prior to day 1 (PET imaging). Inhaled or topical steroids, and adrenal&#xD;
             replacement steroid &gt;10 mg daily prednisone equivalent, are permitted in the absence&#xD;
             of active autoimmune disease.&#xD;
&#xD;
          2. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy.&#xD;
&#xD;
          3. Has symptomatic central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
               -  Note: Subjects with asymptomatic CNS metastases are allowed to enter the study.&#xD;
&#xD;
               -  Note: Subjects with previously treated brain metastases may participate provided&#xD;
                  they are clinically stable and not using steroids with &gt; 10 mg daily prednisone&#xD;
                  equivalent for at least 7 days prior to trial treatment.&#xD;
&#xD;
          4. Has an active autoimmune disease requiring systemic steroid treatment within the past&#xD;
             3 months or a documented history of clinically severe autoimmune disease, or a&#xD;
             syndrome that requires systemic steroids.&#xD;
&#xD;
          5. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          6. Has an active infection requiring systemic therapy.&#xD;
&#xD;
          7. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          8. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          9. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 23 weeks after the last dose of trial treatment.&#xD;
&#xD;
         10. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4&#xD;
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or immune checkpoint pathways.&#xD;
&#xD;
         11. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         12. Has known active Hepatitis B or C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joop de Langen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute-Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Egbert Smit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute-Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joop de Langen, MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>9111</phone_ext>
    <email>j.d.langen@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Mahn, MSc</last_name>
    <phone>+3120512</phone>
    <phone_ext>2974</phone_ext>
    <email>m.mahn@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MeanderMC</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Herder, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUmc</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Idris Bahce, MD</last_name>
      <phone>+3120444</phone>
      <phone_ext>4782</phone_ext>
      <email>i.bahce@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1060CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joop de Langen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonne Biesma, MD, PhD</last_name>
      <email>b.biesma@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Maas, MD</last_name>
      <email>k.maas@mchaaglanden.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Samii, MD</last_name>
      <email>s.samii@dz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasper Smit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisanne Kastelijn, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR WT</keyword>
  <keyword>negative EML4-ALK fusion</keyword>
  <keyword>eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

